49 completed. 49 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 49 | Completed 49 |
| Phase 2 | 13 | Completed 13 |
Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults 20vPnC, 13vPnC - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 400 | 2025-07-06 | 2026-02-25 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| Clinical Trial of PCV24 in Children Aged 2-17 Years Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 119 | 2024-09-07 | 2026-01-28 |
| Study of Gamma PN3 in the Elderly Gamma PN3, Prevnar - Pneumonia, Pneumococcal | Phase 1 | Completed | GPN Vaccines | 105 | 2024-08-26 | 2025-05-11 |
| Clinical Trial of PCV24 in Adults Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Pneumovax® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 170 | 2024-06-21 | 2025-04-16 |
| Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 230 | 2024-04-27 | 2026-08-17 |
| A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Sinovac PCV13, PREVNAR 13 - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Research and Development Co., Ltd. | 140 | 2024-01-04 | 2026-01-28 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-09-25 |
| Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23 - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 240 | 2023-11-19 | 2024-11-07 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 90 | 2023-04-19 | 2024-07-29 |
| Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. Gamma-PN3, Prevenar-13, Pneumovax-23 - Pneumococcal Infections | Phase 1 | Completed | GPN Vaccines | 118 | 2023-01-16 | 2024-09-05 |
| Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13), Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13) - Pneumococcal Infections | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 310 | 2023-01-03 | 2026-01-28 |
| Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age Candidate-1, Candidate-2, Candidate-3 - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 394 | 2022-08-15 | 2024-04-18 |
| Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) V116, PNEUMOVAX™23 - Pneumococcal Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 102 | 2021-02-04 | 2023-10-04 |
| A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator ASP3772, PCV13 - Healthy Volunteers, Pneumococcal Disease | Phase 1 | Completed | Affinivax, Inc. | 75 | 2020-09-22 | 2022-06-06 |
| Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults EuPCV15, Prevenar13 - Pneumococcal Disease | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-05-28 | 2021-10-07 |
| Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infections, Streptococcal Infections | Phase 1 | Completed | CanSino Biologics Inc. | 237 | 2020-05-18 | 2022-10-31 |
| A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) V116, Pneumovax™23 - Pneumonia, Pneumococcal | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 600 | 2019-12-06 | 2022-09-16 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) V114, Pneumococcal 13-valent Conjugate Vaccine (PCV13), Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV) - Pneumococcal Infections | Phase 1 | Completed | Merck Sharp & Dohme LLC | 133 | 2019-04-02 | 2025-01-15 |
Showing 20 of 49. Sign in to see all of them.
Pneumonia, Pneumococcal (8) · Pneumonia (3) · HIV Infections (2) · Pneumonia, Bacterial (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Bacterial Infections (1) · Streptococcal Infections (1)
Bacterial Infections and Mycoses (49) · Gram-Positive Bacterial Infections (49) · Infections (49) · Bacterial Infections (48) · Streptococcal Infections (48) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Infections (12) · Pneumonia (9) · Pneumonia, Bacterial (7) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2)
13-valent pneumococcal vaccine (13) · 23-valent pneumococcal capsular polysaccharide vaccine (8) · Heptavalent Pneumococcal Conjugate Vaccine (8) · Pneumococcal Vaccines (8) · Sodium Chloride (2) · Vaccines, Combined (2) · 10-valent pneumococcal conjugate vaccine (1) · PHiD-CV vaccine (1) · Pentavac (1) · Tetanus Toxoid (1)
Pfizer (7) · Merck Sharp & Dohme LLC (6) · Sinovac Life Sciences Co., Ltd. (4) · GPN Vaccines (3) · Centers for Disease Control and Prevention (2) · GlaxoSmithKline (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · PATH (2) · Reinovax Biologics Co., LTD (2) · Sanofi (2) · Sanofi Pasteur, a Sanofi Company (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Affinivax, Inc. (1) · CIHR Canadian HIV Trials Network (1) · CanSino Biologics Inc. (1)
United States (14) · China (10) · Australia (3) · Switzerland (3) · Bangladesh (2) · Belgium (2) · Germany (2) · Japan (2) · Kenya (2) · South Korea (2) · Canada (1) · France (1) · Puerto Rico (1) · The Gambia (1) · United Kingdom (1)
Kai Chu (2) · Anthony Scott, MD, PhD (1) · Christopher Bailey, Bsc, PhD (1) · Ed Clarke, MD PhD (1) · Evelyn Hatzenbichler, PhD (1) · Harry L Keyserling, MD (1) · James King, Jr, M.D. (1) · Karen Miernyk, MS (1) · Lisa A Jackson, MD, MPH (1) · M C Steinhoff, MD (1)
PMID 30689507, PMID 15882530, PMID 17391816, PMID 18799552, PMID 19522655, PMID 20435707, PMID 22353593, PMID 23123106, PMID 23131206, PMID 23153437, PMID 23300160, PMID 23535358, PMID 23967126, PMID 24176494, PMID 25741971, PMID 25913828, PMID 26143615, PMID 26668712, PMID 29132988, PMID 31056427, PMID 31843266, PMID 33545022, PMID 35690500, PMID 36116461, PMID 36882898, PMID 37389808, PMID 38360475, PMID 39384037, PMID 39883948
2009 (1), 2015 (1), 2019 (1)